Fundraising Fox
METHYS DX
1 known investors
Find your way into METHYS DX
Sign up to see every warm intro you have to METHYS DX
- Paths you didn't know you had: your email and LinkedIn already hold routes to the METHYS DX team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
METHYS Dx develops liquid biopsy tests based on panels of methylation markers to characterize circulating tumor DNA (ctDNA) in biological fluids such as blood. Its tests target several common cancers to support disease prognosis, monitor tumor progression, and detect recurrences early, positioned as a lower-cost alternative to NGS testing.
Founders & leadership
Investors · 1
Frequently asked questions
- What does METHYS DX do?
- METHYS Dx develops liquid biopsy tests based on panels of methylation markers to characterize circulating tumor DNA (ctDNA) in biological fluids such as blood. Its tests target several common cancers to support disease prognosis, monitor tumor progression, and detect recurrences early, positioned as a lower-cost alternative to NGS testing.
- Who founded METHYS DX?
- METHYS DX was founded by Valerie Taly.
- Who are METHYS DX's investors?
- METHYS DX's investors include Creative Destruction Lab (CDL).